Myricx Bio further strengthens its clinical team and US presence with the appointment of David Ellis

London, UK, 17 September 2025 – Myricx Bio (‘Myricx’), a UK-based biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce the appointment of David Ellis, PhD, in the newly created position of VP, Regulatory Affairs, based in the USA.

David joins Myricx from ADC Therapeutics where he served for over a decade as Vice President, Head of Regulatory Affairs and brings over 27 years of experience in regulatory affairs working for a range of pharma and biotech companies. Previously, he was at Aptalis Pharma where he held the role of Vice President of Global Regulatory Affairs and at Cephalon as its Senior Director of Regulatory Affairs. Earlier roles include independent consultancy and Assistant Vice President in Global Regulatory Affairs at Pfizer and Wyeth Research.

David holds a Ph.D. in Molecular Biology from the University of Nottingham.

Steen Lisby, MD, DMSc at Myricx Bio said:

We are delighted to welcome David to the Myricx team. With several of our N-myristoyltransferase inhibitor (NMTi)-ADC programs progressing towards clinical development and having nominated our lead development candidate, we expect to enter human clinical trials in 2026. David’s extensive global regulatory and ADC expertise will be crucial in driving our regulatory strategies at this pivotal time.

David Ellis, PhD, VP, Regulatory Affairs at Myricx Bio said:

It’s an exciting time to join Myricx as it advances its programs towards clinical development. With my background in the ADC space and my industry experiences in regulatory affairs, I look forward to using my expertise and working with the Myricx team to further develop and implement plans to support the clinical development and regulatory submissions of its NMTi-ADC drug candidates.

Over the past 12 months since securing its £90 million ($114 million) Series A financing, Myricx has moved to dedicated facilities in London and expanded its leadership, clinical and R&D teams. David is Myricx’s second US-based team member, following the appointment of Penny Fatato as Global Head of Clinical Operations in August, reflecting its growth ambitions. Myricx plans further appointments in the future in the UK and USA.